Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Assessing the efficacy-effectiveness gap for cancer therapies: A comparison of overall survival and toxicity between clinical trial and population-based, real-world data for contemporary parenteral cancer therapeutics.
Phillips CM, Parmar A, Guo H, Schwartz D, Isaranuwatchai W, Beca J, Dai W, Arias J, Gavura S, Chan KKW. Phillips CM, et al. Among authors: arias j. Cancer. 2020 Apr 15;126(8):1717-1726. doi: 10.1002/cncr.32697. Epub 2020 Jan 8. Cancer. 2020. PMID: 31913522 Free article.
Real-world outcomes of FOLFIRINOX vs gemcitabine and nab-paclitaxel in advanced pancreatic cancer: A population-based propensity score-weighted analysis.
Chan KKW, Guo H, Cheng S, Beca JM, Redmond-Misner R, Isaranuwatchai W, Qiao L, Earle C, Berry SR, Biagi JJ, Welch S, Meyers BM, Mittmann N, Coburn N, Arias J, Schwartz D, Dai WF, Gavura S, McLeod R, Kennedy ED. Chan KKW, et al. Among authors: arias j. Cancer Med. 2020 Jan;9(1):160-169. doi: 10.1002/cam4.2705. Epub 2019 Nov 13. Cancer Med. 2020. PMID: 31724340 Free PMC article.
Considerations for Developing a Reassessment Process: Report from the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration's Reassessment and Uptake Working Group.
Dai WF, Arciero V, Craig E, Fraser B, Arias J, Boehm D, Bosnic N, Caetano P, Chambers C, Jones B, Lungu E, Mitera G, Potashnik T, Reiman A, Ritcher T, Beca JM, Denburg A, Mercer RE, Parmar A, Tadrous M, Takhar P, Chan KKW, On Behalf Of The CanREValue Collaboration Reassessment And Uptake Working Group. Dai WF, et al. Among authors: arias j. Curr Oncol. 2021 Oct 16;28(5):4174-4183. doi: 10.3390/curroncol28050354. Curr Oncol. 2021. PMID: 34677272 Free PMC article.
Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer.
Arciero V, Luo J, Parmar A, Dai WF, Beca JM, Raphael MJ, Isaranuwatchai W, Habbous S, Tadrous M, Earle CC, Biagi JJ, Mittmann N, Arias J, Gavura S, Chan KKW. Arciero V, et al. Among authors: arias j. JNCI Cancer Spectr. 2022 Jul 1;6(4):pkac047. doi: 10.1093/jncics/pkac047. JNCI Cancer Spectr. 2022. PMID: 35758620 Free PMC article.
Comparison of Use of Neoadjuvant Systemic Treatment for Breast Cancer and Short-term Outcomes Before vs During the COVID-19 Era in Ontario, Canada.
Habbous S, Tai X, Beca JM, Arias J, Raphael MJ, Parmar A, Crespo A, Cheung MC, Eisen A, Eskander A, Singh S, Trudeau M, Gavura S, Dai WF, Irish J, Krzyzanowska M, Lapointe-Shaw L, Naipaul R, Peacock S, Yeung L, Forbes L, Chan KKW. Habbous S, et al. Among authors: arias j. JAMA Netw Open. 2022 Aug 1;5(8):e2225118. doi: 10.1001/jamanetworkopen.2022.25118. JAMA Netw Open. 2022. PMID: 35917122 Free PMC article.
Comparative Effectiveness of FOLFIRINOX Versus Gemcitabine and Nab-paclitaxel in Initially Unresectable Locally Advanced Pancreatic Cancer: A Population-based Study to Assess Subsequent Surgical Resection and Overall Survival.
Dai WF, Habbous S, Saluja R, Beca JM, Raphael M, Arias J, Gavura S, Earle CC, Biagi JJ, Coburn N, Chan KKW. Dai WF, et al. Among authors: arias j. Clin Oncol (R Coll Radiol). 2023 May;35(5):e303-e311. doi: 10.1016/j.clon.2023.02.008. Epub 2023 Feb 16. Clin Oncol (R Coll Radiol). 2023. PMID: 36863956
1,117 results